Cytotoxicity and antimicrobial studies of 1,6,8- trihydroxy-3-methyl-anthraquinone (emodin) isolated from the leaves of Cassia nigricans Vahl

Emodin was isolated from the ethyl acetate extract of the leaves of Cassia nigricans Vahl. The structure of the emodin was established by chemical spectroscopy. The LC50 (lower – upper limits) of the emodinwas 42.77 (11.80 – 72.94) ìg/ml. Emodin was found to be highly cytotoxic. It showed significant antimicrobial activity on some common pathogens. The isolation of this active principle emodin, from the leaves of Cassia nigricans for the first time and the antimicrobial activity of the compound are reported in the present study. The isolation of the active principle justifies the use of the leaves of C. nigricans in herbal medicine for the treatment of skin diseases and gastro-intestinal disorders

Physico-chemical characterization and cytotoxicity studies of seed extracts of Khaya senegalensis (Desr.) A. Juss.

The seeds of Khaya senegalensis were extracted using petroleum ether and methanol with the aim of determining the physico-chemical properties of the seed oil and the cytotoxicity of the two extracts. Therefractive index of the oil was found to be 1.458, while the relative density was 0.953. The iodine and saponification values were 88.40 and 195.58, respectively. The peroxide and acid values were 4.6 and2.69, respectively. Brine shrimp lethality bioassay of petroleum ether and methanol extracts of the seeds showed that the extracts were moderately cytotoxic at high concentration. The LC50 values usingProbit analysis method for petroleum ether and methanol extracts were 827.39 and 51.79 ìg/ml, respectively. Therefore, the seed oil of K. senegalensis was found to be non-drying oil and the extractsfrom the seeds may contain bioactive compounds of potential therapeutic and prophylactic significance

Antimicrobial activity of extracts of leaves of Pseudocedrela kotschyi (Schweinf.) Harms

The aim of the experiment was to investigate the phytochemical composition and antimicrobial activity of extracts of Pseudocedrela kotschyi (Schweinf.) Harms used in folklore medicine in order to authenticate some of its therapeutic claims. The antimicrobial activity of petroleum ether, ethyl acetate and methanol extracts of the leaves of P. kotschyi was investigated against Staphylococcus aureus, Salmonella typhi, Streptococcus pyogenes, Candida albicans and Escherichia coli, using agar diffusion technique. Carbohydrates, reducing sugars, glycosides, cardiac glycosides, saponins, flavonoids, alkaloids, steroids and tannins were present in the leaves of P. kotschyi. The results of the antimicrobial activity showed that the ethyl acetate extract was more effective against all the test microorganisms than the methanol extract. The petroleum ether extract was resistant to all the test microorganisms. The minimum inhibitory concentration (MIC) exhibited by the ethyl acetate extract against the microorganisms was 10 mg/ml, except for S. typhi and C. albicans that had the value of 20 mg/ml. The methanol extract was active only against S aureus, S. typhi and E coli, and the MIC value for the microorganisms was 20 mg/ml. The lowest value of minimum bactericidal concentration exhibited by the ethyl acetate extract was 20 mg/ml, and the value was obtained for S. aureus S. pyogenes and E. coli. In conclusion, the leaves of P. kotschyi are a potential source of novel antimicrobial agents.Key words: Pseudocedrela kotschyi, leaves, extracts, phytochemical composition, antimicrobial activity

Diets containing sea cucumber (Isostichopus badionotus) meals are hypocholesterolemic in young rats

Peer reviewedPublisher PD

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality

Background and purpose: Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. Methods: We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). Results: There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. Conclusions: During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT

Global impact of COVID-19 on stroke care

Background: The COVID-19 pandemic led to profound changes in the organization of health care systems worldwide. Aims: We sought to measure the global impact of the COVID-19 pandemic on the volumes for mechanical thrombectomy, stroke, and intracranial hemorrhage hospitalizations over a three-month period at the height of the pandemic (1 March–31 May 2020) compared with two control three-month periods (immediately preceding and one year prior). Methods: Retrospective, observational, international study, across 6 continents, 40 countries, and 187 comprehensive stroke centers. The diagnoses were identified by their ICD-10 codes and/or classifications in stroke databases at participating centers. Results: The hospitalization volumes for any stroke, intracranial hemorrhage, and mechanical thrombectomy were 26,699, 4002, and 5191 in the three months immediately before versus 21,576, 3540, and 4533 during the first three pandemic months, representing declines of 19.2% (95%CI, −19.7 to −18.7), 11.5% (95%CI, −12.6 to −10.6), and 12.7% (95%CI, −13.6 to −11.8), respectively. The decreases were noted across centers with high, mid, and low COVID-19 hospitalization burden, and also across high, mid, and low volume stroke/mechanical thrombectomy centers. High-volume COVID-19 centers (−20.5%) had greater declines in mechanical thrombectomy volumes than mid- (−10.1%) and low-volume (−8.7%) centers (p < 0.0001). There was a 1.5% stroke rate across 54,366 COVID-19 hospitalizations. SARS-CoV-2 infection was noted in 3.9% (784/20,250) of all stroke admissions. Conclusion: The COVID-19 pandemic was associated with a global decline in the volume of overall stroke hospitalizations, mechanical thrombectomy procedures, and intracranial hemorrhage admission volumes. Despite geographic variations, these volume reductions were observed regardless of COVID-19 hospitalization burden and pre-pandemic stroke/mechanical thrombectomy volumes

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.

BACKGROUND AND PURPOSE: Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year. METHODS: We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020). RESULTS: There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths. CONCLUSIONS: During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT

Isolation and Characterization of Lup-20(29)-ene-3, 28-diol (Betulin) from the Stem-Bark of Adenium obesum ( Apocynaceae)

Purpose: To isolate and characterize chemical compound(s) of biological importance from the stembark of the plant, Adenium obesum . Methods: The stem-bark, after air-drying and powdering, was subjected to sequential hot-continuous extraction using petroleum spirit (60 - 80 oC) and methanol in that order. The petroleum spirit extract was chromatographed using thin layer and column chromatographic techniques. Recrystallization was used to further purify the isolated compound. Characterization of the isolated compound was by melting point, as well as by 1H and 13C nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry (MS). Results: A triterpenoid (lup-20(29)-ene-3, 28-diol), commonly known as betulin, was isolated from the crude petroleum ether extract of the plant stem-bark. The isolated compound’s melting point was 256 - 257 °C. The name, betulin, was assigned to this compound by comparison of its spectroscopic data from 1H-NMR, 13C-NMR and MS analysis with those of authenticated samples reported in the literature. Conclusion: A known compound, betulin ( lup-20(29)-ene-3, 28-diol) was isolated from the petroleum ether extract of the stem-bark of Adenium obesum